Biovie Inc (BIVI)

Jan 26, 2025, 10:00 AM EST - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation

Jan 22, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect

Jan 19, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out

Jan 15, 2025, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 6 weeks ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect

Jan 2, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation

Dec 24, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out

Dec 22, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out

Dec 18, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect

Dec 15, 2024, 10:00 AM EST - 2 months ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Dec 11, 2024, 2:00 PM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation

Oct 28, 2024, 4:10 PM EDT - 4 months ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 4 months ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 24, 2024, 4:10 PM EDT - 4 months ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 23, 2024, 3:24 PM EDT - 4 months ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 15, 2024, 8:00 AM EDT - 4 months ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 11, 2024, 9:00 AM EDT - 4 months ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Sep 25, 2024, 4:05 PM EDT - 5 months ago

BioVie Inc. Announces Closing of Public Offering

Sep 24, 2024, 2:08 PM EDT - 5 months ago

Crude Oil Gains Over 1%; BioVie Shares Plunge

Sep 23, 2024, 10:26 PM EDT - 5 months ago

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 4:05 PM EDT - 5 months ago

BioVie Inc. Announces Proposed Public Offering

Sep 16, 2024, 8:00 AM EDT - 5 months ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 6 months ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Aug 27, 2024, 8:45 AM EDT - 6 months ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 8, 2024, 6:00 AM EDT - 7 months ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 6, 2024, 4:40 PM EDT - 7 months ago

BioVie Inc. Announces Reverse Stock Split

Jul 5, 2024, 9:00 AM EDT - 8 months ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Jun 21, 2024, 9:00 AM EDT - 8 months ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

Jun 20, 2024, 8:00 AM EDT - 8 months ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 12, 2024, 8:24 AM EDT - 9 months ago

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

May 22, 2024, 8:00 AM EDT - 9 months ago

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

Apr 29, 2024, 8:00 AM EDT - 10 months ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Apr 25, 2024, 8:00 AM EDT - 10 months ago

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Apr 18, 2024, 8:00 AM EDT - 11 months ago

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Apr 12, 2024, 9:00 AM EDT - 11 months ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Mar 26, 2024, 10:30 AM EDT - 11 months ago

Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation

Mar 19, 2024, 7:00 AM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

Mar 17, 2024, 11:00 PM EDT - 1 year ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

Mar 11, 2024, 8:00 AM EDT - 1 year ago

BioVie Announces Pipeline Update and Near-Term Clinical Priorities